Arrowhead’s ARO-APOC3 adds Phase 2 dyslipidemia data
The registry entry creates a public checkpoint for a lipid-related drug candidate, without showing from this notice whether it is safe or effective.

Arrowhead Pharmaceuticals’ ARO-APOC3 program added a completed Phase 2 dyslipidemia trial with results on ClinicalTrials.gov on Nov. 20, according to registry entry NCT05413135.
The Nov. 20 clinical registry update matters because Phase 2 trials test a therapeutic intervention in patients before any larger Phase 3 program; this record concerns adults with dyslipidemias, a group of lipid-related disorders.
ClinicalTrials.gov lists Arrowhead Pharmaceuticals as the sponsor of the trial. The intervention is ARO-APOC3, and the condition is dyslipidemias, according to the registry record.
The record’s NCT number is the ClinicalTrials.gov identifier, an eight-digit code used to track a registered clinical study. ClinicalTrials.gov defines a clinical trial as an interventional study involving human volunteers intended to add to medical knowledge.
The registry status does not by itself show that ARO-APOC3 improved lipid measures, reduced cardiovascular events or met any regulatory threshold. It also does not establish that the intervention is safe or effective for people outside the adults with dyslipidemias covered by the trial record.
For patients and clinicians, the practical significance is limited to trial progress and public availability of registry results. Any conclusions about efficacy, safety, dose or use would require the actual clinical data and regulatory review.
Source: clinical registry, ClinicalTrials.gov, Nov. 20, 2026
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

